Skip to main content

Table 1 Participant demographics and baseline characteristics. All Participants as Treated

From: A randomized trial evaluating the safety profile of sugammadex in high surgical risk ASA physical class 3 or 4 participants

Characteristic

Sugammadex 2 mg/kg

N = 105

Sugammadex 4 mg/kg

N = 107

Sugammadex 16 mg/kg

N = 68

Neostigmine/Glycopyrrolate

N = 51

Gender

 Male

59 (56.2)

68 (63.6)

39 (57.4)

36 (70.6)

 Female

46 (43.8)

39 (36.4)

29 (42.6)

15 (29.4)

Age (yrs): Median (Range)

70 (35 to 87)

70 (24 to 92)

71 (44 to 90)

68 (35 to 89)

 < 65, n (%)

28 (27)

41 (38)

20 (29)

19 (37)

 ≥65 to ≤74, n (%)

39 (37)

29 (27)

25 (37)

20 (39)

 > 74, n (%)

38 (36)

37 (35)

23 (34)

12 (24)

BMI: Mean ± SD (kg/m2)

28.1 ± 5.5

28.4 ± 5.3

28.6 ± 5.0

29.3 ± 5.4

 Median (range)

27.1 (15.8 to 39.6)

28.4 (16.8 to 39.8)

28.5 (16.4 to 39.0)

28.9 (15.7 to 39.0)

 < 30 kg/m2, n (%)

67 (63.8)

65 (60.7)

41 (60.3)

26 (51.0)

 ≥30 to < 40 kg/m2, n (%)

38 (36.2)

42 (39.3)

27 (39.7)

25 (49.0)

ASA Class: ASA Class 3, n (%)

79 (75.2)

79 (73.8)

51 (75.0)

38 (74.5)

 ASA Class 4, n (%)

26 (24.8)

28 (26.2)

17 (25.0)

13 (25.5)

Creatinine Clearance†

(mL/min)

 Mean ± SD

88.5 ± 33.9

94.5 ± 40.6

92.8 ± 49.2

101.5 ± 46.3

 Median (range)

82.6 (27.4 to 176.0)

91.1 (29.3 to 227.5)

83.8 (30.1 to 368.0)

91.3 (39.7 to 268.9)

 ≤30, n (%)

1 (1.0)

1 (0.9)

0

0

 > 30 to ≤50, n (%)

6 (5.7)

10 (9.3)

4 (5.9)

2 (3.9)

 > 50 to ≤80, n (%)

42 (40.0)

33 (30.8)

25 (36.8)

16 (31.4)

 > 80, n (%)

52 (49.5)

54 (50.5)

34 (50.0)

26 (51.0)

 Missing, n (%)

4 (3.8)

9 (8.4)

5 (7.4)

7 (13.7)

Rocuronium, n (%)

65 (61.9)

66 (61.7)

68 (100)

32 (62.7)

 Mean ± SD, (mg/kg)

1.14 ± 0.62

1.60 ± 0.76

1.60 ± 0.96

1.01 ± 0.50

 Median (range), (mg/kg)

1.01 (0.36 to 3.23)

1.45 (0.39 to 3.92)

1.33 (0.43 to 5.44)

0.83 (0.33 to 2.14)

Vecuronium (mg/kg), n (%)

40 (38.1)

41 (38.3)

0

19 (37.3)

 Mean ± SD, (mg/kg)

0.14 ± 0.08

0.26 ± 0.27

n.a.

0.14 ± 0.07

 Median (range), (mg/kg)

0.12 (0.05 to 0.49)

0.19 (0.06 to 1.73)

n.a.

0.13 (0.05 to 0.34)

  1. Abbreviations: NMBA Neuromuscular blocking agent, SD Standard deviation, n.a Not applied
  2. †Creatinine clearance based on Cockcroft-Gault formula
Back to article page

BMC Anesthesiology

ISSN: 1471-2253

Contact us